DxS enters Scorpions deal with SIRS-Lab
This article was originally published in Clinica
Manchester, UK-based molecular diagnostics firm DxS has licensed its Scorpions real-time PCR technology to German sepsis specialist SIRS-Lab for an undisclosed fee. The EU-wide agreement allows SIRS-Lab to incorporate DxS’ technology into its Siqnature sepsis prediction and monitoring test, which it aims to make commercially available in 2009. The Siqnature allows the early detection of sepsis by differentiating between infectious and non-infectious states in patients – the test is based on proprietary transcriptomic biomarkers that indicate sepsis earlier and more reliably than currently possible, claims Jena-based SIRS-Lab. The deal between the two firms also includes an option for worldwide IVD utilisation of the Scorpions technology.